On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company.
These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple sclerosis; it is protected by several patents, the latest of which expires in 2035.
Founded in 2008, Juvise Pharmaceuticals is an international pharmaceutical company based in Villeurbanne, France. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry and rheumatology, making them accessible to more than 4.4 million patients every year.
This acquisition is a strategic step for Juvisé as it expands its portfolio with the first patent protected product with strong development potential over the coming years. The financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 17th Pharmaceutical acquisition of 2024. Throughout 2023, 107 Pharmaceutical deals were reported.
